We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Researchers Just Days Away from Testing Potential COVID-19 Vaccine on Humans

By HospiMedica International staff writers
Posted on 02 Apr 2020
Print article
Image: Researchers just days away from testing potential COVID-19 vaccine on humans (Photo courtesy of MIGAL Galilee Research Institute)
Image: Researchers just days away from testing potential COVID-19 vaccine on humans (Photo courtesy of MIGAL Galilee Research Institute)
Researchers from the MIGAL Galilee Research Institute (Qiryat Shemona, Israel) are just days away from finishing the production of the active component of a coronavirus vaccine that could be tested on humans by as soon as June 1. Funded by Israel’s Ministry of Science & Technology, MIGAL’s researchers have developed an effective vaccine against avian coronavirus Infectious Bronchitis Virus (IBV) that is being adapted to create a human vaccine against COVID-19.

Research conducted at MIGAL revealed that the poultry coronavirus has high genetic similarity to the human COVID-19, and that it uses the same infection mechanism, a fact that increases the likelihood of achieving an effective human vaccine in a very short period of time. MIGAL has now made the required genetic adjustments to adapt the vaccine to COVID-19, the human strain of coronavirus, and is working to achieve the safety approvals that will enable in-vivo testing, enable the initiation of production of a vaccine to counter the coronavirus epidemic. The researchers have proved the effectiveness of the vaccine in preclinical trials carried out at the Volcani Institute.

“Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development. Our goal is to produce the vaccine during the next 8-10 weeks, and to achieve safety approval in 90 days,” said David Zigdon, CEO of MIGAL Galilee Research Institute. “This will be an oral vaccine, making it particularly accessible to the general public. We are currently in intensive discussions with potential partners that can help accelerate the in-human trials phase and expedite the completion final product development and regulatory activities.”

“The scientific framework for the vaccine is based on a new protein expression vector, which forms and secretes a chimeric soluble protein that delivers the viral antigen into mucosal tissues by self-activated endocytosis (a cellular process in which substances are brought into a cell by surrounding the material with cell membrane, forming a vesicle containing the ingested material), causing the body to form antibodies against the virus. In pre-clinical (IN-VIVO) trials, MIGAL’s researchers have demonstrated that the oral vaccination induces high levels of specific anti-IBV antibodies,” said Dr. Chen Katz, MIGAL’s Biotechnology Group Leader.

Meanwhile, researchers at the Israel Institute for Biological Research (IIBR; Ness Ziona, Israel) have reportedly begun testing a COVID-19 vaccine prototype on rodents. After being ordered by Israeli Prime Minister Benjamin Netanyahu to join the fight against the coronavirus pandemic, the IIBR has formed three groups for developing a vaccine against the COVID-19 disease and other groups for researching potential treatments. The IIBR is also collecting plasma from people who have recovered from COVID-19 infection to aid their research and is sampling various COVID-19 testing kits available in the market before the government places large orders for them.

Related Links:
MIGAL Galilee Research Institute
Israel Institute for Biological Research (IIBR)


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Patient Monitor
CMS9100PLUS

Print article

Channels

Critical Care

view channel
Image: Detecting heart diseases using AI and the ECG (Photo courtesy of 123RF)

AI Technology Boosts ECG Capabilities for Early Heart Disease Diagnosis

Cardiovascular diseases often remain undetected until a critical event like a heart attack or stroke occurs. Early identification is key to improving outcomes, but the absence of clear symptoms complicates... Read more

Surgical Techniques

view channel
Image: Real-time navigation is a useful tool for ablation procedures to destroy tumors in the liver (Photo courtesy of University of Cincinnati)

Real-Time Navigation Found To Be Useful Tool for Liver Cancer Procedures

Liver cancer, ranking as the world's fourth most common cause of cancer-related deaths, presents a significant health challenge. For certain patients, ablation offers a less invasive alternative to traditional... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The new eye-safe laser technology can diagnose traumatic brain injury (Photo courtesy of 123RF)

Novel Diagnostic Hand-Held Device Detects Known Biomarkers for Traumatic Brain Injury

The growing need for prompt and efficient diagnosis of traumatic brain injury (TBI), a major cause of mortality globally, has spurred the development of innovative diagnostic technologies.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.